Change of formulation decreases venous irritation in breast cancer patients receiving epirubicin-Reference-Cited by-同舟云学术

Change of formulation decreases venous irritation in breast cancer patients receiving epirubicin

Published:2011-04-26 Issue:5 Volume:20 Page:951-955
ISSN:0941-4355
Container-title:Supportive Care in Cancer
language:en
Short-container-title:Support Care Cancer

Author:

Nagata Kenichiro,Egashira Nobuaki,Yamada Takaaki,Watanabe Hiroyuki,Yamauchi Yui,Oishi Ryozo

Publisher

Springer Science and Business Media LLC

Subject

Oncology

Link

http://link.springer.com/content/pdf/10.1007/s00520-011-1166-0.pdf

Reference10 articles.

1. Glück S (2005) Adjuvant chemotherapy for early breast cancer: optimal use of epirubicin. Oncologist 10:780–791

2. Cersosimo RJ, Hong WK (1986) Epirubicin: a review of the pharmacology, clinical activity, and adverse effects of an adriamycin analogue. J Clin Oncol 4:425–439

3. Suga Y, Kumazaki M, Nishigami J et al (2009) Improvement of epirubicin-induced phlebitis to switch from liquid preparation to lyophilized formulation. Gan To Kagaku Ryoho 36:93–96

4. Jackson A (1998) Infection control–a battle in vein: infusion phlebitis. Nurs Times 94:68–71

5. Kuwahara T, Asanami S, Kawauchi Y et al (1999) Experimental infusion phlebitis: tolerance pH of peripheral vein. J Toxicol Sci 24:113–121

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The pharmacist’s role in reducing infusion-related phlebitis;American Journal of Health-System Pharmacy;2023-05-03

2. A 5% Glucose Solution for the Liquid Formulation Gemcitabine Solvent Decreases Gemcitabine-induced Vascular Pain;Anticancer Research;2021-12-29

3. Identifying Risk Factors for Anthracycline Chemotherapy-induced Phlebitis in Women with Breast Cancer: An Observational Study;Clinical Oncology;2021-04

4. Risk Factors for Gemcitabine-Induced Vascular Pain in Patients With Pancreatic Cancer;Annals of Pharmacotherapy;2020-10-23

5. Outcomes of Clinical Pharmacy Research Aimed at Avoiding or Reducing Cancer Chemotherapy-induced Adverse Reaction;Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences);2020-09-10